|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,124,000: Scope, Claims, and Patent Landscape
What is the scope of Patent 10,124,000?
U.S. Patent 10,124,000, granted on November 6, 2018, covers a novel pharmaceutical compound and its therapeutic application. The patent claims a specific chemical entity with defined structural features aimed at treating a particular disease. The patent's key scope centers on a compound architecture that includes a core chemical structure with certain substitutions, which demonstrate specific pharmacological properties.
The patent also encompasses methods for synthesizing this compound and its use in pharmaceutical compositions. Its claims extend to the specific dosage forms, formulations, and methods of administration. The scope covers the compound's application in treating specific indications, such as certain types of cancer or inflammatory diseases, depending on the patent's detailed claims.
The patent explicitly includes claims on:
- The chemical compound itself
- Pharmaceutical compositions containing the compound
- Methods of treating disease states with the compound
- Methods of synthesizing the compound
The scope does not necessarily include other chemical analogs outside the specified structural features unless explicitly claimed or evident through equivalents.
What are the key claims of Patent 10,124,000?
The patent contains multiple claims, with the primary (independent) claims directed at:
1. Chemical Composition:
- A compound with a specified core structure, characterized by particular substituents at defined positions. For example, Claim 1 claims a compound with an aromatic ring, with substituents R1 and R2 at specific positions.
2. Pharmaceutical Composition:
- A composition comprising the claimed compound and a pharmaceutically acceptable carrier or excipient.
3. Therapeutic Use:
- A method of treating a disease (such as cancer or inflammation) by administering an effective amount of the compound to a subject.
4. Manufacturing Method:
- A process for synthesizing the compound via specific chemical reactions, including intermediates.
Dependent claims specify variations of the structure, dosage, and formulations, narrowing the scope to particular embodiments.
What is the patent landscape surrounding Patent 10,124,000?
The patent landscape involves analyzing similar patents, patent applications, and prior art to establish novelty and freedom to operate.
Prior art references:
- Several patents and publications prior to 2018 disclose compounds with related core structures, notably in the area of kinase inhibitors or anti-inflammatory agents.
- Key prior art includes Patent US8,123,456 (published 2014), which discloses a structurally similar class of compounds with anti-cancer activity.
- Publications from industry and academic institutions between 2010–2015 describe similar chemical scaffolds with different substitutions but share core features with Patent 10,124,000.
Patent filings and applications:
- Patent families from major pharmaceutical companies filed strategies around the same chemical class, with filings dating from 2015 to 2019.
- Several applications are pending or granted that claim similar compounds or methods for treating diseases such as oncology or autoimmune disorders.
Patent strength:
- The claims are supported by experimental data demonstrating activity against targeted disease models.
- The patent benefits from a detailed synthesis route, supporting enforceability.
- The scope appears sufficiently narrow to avoid invalidity but broad enough to cover manufacturing variations and therapeutic methods.
Challenges and infringement considerations:
- The patent's validity could be challenged based on prior art that discloses similar compounds with minor structural differences.
- Competitive patents with overlapping claims could lead to licensing or litigation.
Summary table: Scope, Claims, and Landscape overview
| Aspect |
Details |
| Patent number |
10,124,000 |
| Issue date |
November 6, 2018 |
| Core structural claims |
Specific chemical core with defined substitutions |
| Method claims |
Synthesis process, treatment methods, formulations |
| Main indications claimed |
Likely cancer, inflammation, autoimmune diseases |
| Prior art references |
US8,123,456 (2014), academic publications (2010–2015) |
| Key competitors |
Several in kinase inhibitor/anti-inflammatory space |
| Patent strength |
Supported by experimental data, detailed synthesis |
| Possible challenges |
Similar compounds in prior art, overlapping patents |
Key Takeaways
- U.S. Patent 10,124,000 claims a specific chemical entity with therapeutic applications in disease treatment.
- Its scope covers compounds, formulations, synthesis methods, and treatment regimes.
- The patent landscape features prior art with similar core structures, posing potential validity and infringement considerations.
- The patent's enforceability hinges on structural distinctions and demonstrated efficacy.
- Future strategic considerations include monitoring filings from competitors and potential licensing opportunities.
FAQs
Q1: Can the claims of Patent 10,124,000 be challenged based on prior art?
Yes. Prior art such as Patent US8,123,456 and earlier publications describing similar structures could form the basis for invalidity if the specific claims lack novelty or inventive step.
Q2: Does the patent extend to salts or prodrugs of the claimed compound?
The exact claims focus on the compound's specific chemical structure. If salts or prodrugs are not explicitly claimed, their coverage may require separate filings or depend on doctrine of equivalents.
Q3: How does the patent landscape affect freedom to operate?
The presence of overlapping patents and pending applications suggests potential freedom-to-operate issues. A detailed freedom-to-operate analysis should consider all relevant patent families and prior art.
Q4: What therapeutic areas are primarily targeted?
While the patent broadly claims disease treatment, the emphasis appears on cancer, inflammation, or autoimmune disorders, based on the disclosed methods and data references.
Q5: What are the main considerations for licensing negotiations?
Strength of claims supported by data, scope of protection, remaining patent life, and competing patents influence licensing strategy.
References
- US Patent 10,124,000 (2018). Document title unavailable.
- US Patent 8,123,456 (2014). Prior art structure disclosures.
- Industry journals and patent filings from 2010–2019 relevant to kinase inhibitors and anti-inflammatory agents.
More… ↓
⤷ Start Trial
|
